Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HLA-B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HLA-B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HLA-B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HLA-B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HLA-B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HLA-B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HLA-B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HLA-B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HLA-B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HLA-B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HLA-B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HLA-B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HLA-B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190370625 | Skin | AK | regulation of hemopoiesis | 65/1910 | 367/18723 | 6.74e-06 | 1.52e-04 | 65 |
GO:190210515 | Skin | AK | regulation of leukocyte differentiation | 50/1910 | 279/18723 | 5.47e-05 | 8.35e-04 | 50 |
GO:000268317 | Skin | AK | negative regulation of immune system process | 67/1910 | 434/18723 | 3.74e-04 | 3.63e-03 | 67 |
GO:00028319 | Skin | AK | regulation of response to biotic stimulus | 53/1910 | 327/18723 | 4.63e-04 | 4.31e-03 | 53 |
GO:19031318 | Skin | AK | mononuclear cell differentiation | 65/1910 | 426/18723 | 6.24e-04 | 5.45e-03 | 65 |
GO:001988226 | Skin | AK | antigen processing and presentation | 22/1910 | 106/18723 | 9.13e-04 | 7.49e-03 | 22 |
GO:00321024 | Skin | AK | negative regulation of response to external stimulus | 61/1910 | 420/18723 | 2.96e-03 | 1.87e-02 | 61 |
GO:004800225 | Skin | AK | antigen processing and presentation of peptide antigen | 14/1910 | 62/18723 | 3.32e-03 | 2.03e-02 | 14 |
GO:001988325 | Skin | AK | antigen processing and presentation of endogenous antigen | 8/1910 | 26/18723 | 3.36e-03 | 2.05e-02 | 8 |
GO:00450886 | Skin | AK | regulation of innate immune response | 34/1910 | 218/18723 | 8.06e-03 | 4.06e-02 | 34 |
GO:000248326 | Skin | AK | antigen processing and presentation of endogenous peptide antigen | 6/1910 | 19/18723 | 9.42e-03 | 4.60e-02 | 6 |
GO:000268318 | Skin | SCCIS | negative regulation of immune system process | 49/919 | 434/18723 | 4.92e-08 | 8.19e-06 | 49 |
GO:190210516 | Skin | SCCIS | regulation of leukocyte differentiation | 35/919 | 279/18723 | 3.43e-07 | 3.03e-05 | 35 |
GO:1903706111 | Skin | SCCIS | regulation of hemopoiesis | 40/919 | 367/18723 | 2.04e-06 | 1.09e-04 | 40 |
GO:0048002111 | Skin | SCCIS | antigen processing and presentation of peptide antigen | 13/919 | 62/18723 | 7.81e-06 | 2.86e-04 | 13 |
GO:0019882111 | Skin | SCCIS | antigen processing and presentation | 17/919 | 106/18723 | 1.52e-05 | 4.90e-04 | 17 |
GO:190313115 | Skin | SCCIS | mononuclear cell differentiation | 39/919 | 426/18723 | 1.42e-04 | 2.90e-03 | 39 |
GO:000283113 | Skin | SCCIS | regulation of response to biotic stimulus | 32/919 | 327/18723 | 1.67e-04 | 3.31e-03 | 32 |
GO:0019883112 | Skin | SCCIS | antigen processing and presentation of endogenous antigen | 7/919 | 26/18723 | 1.94e-04 | 3.69e-03 | 7 |
GO:0002483111 | Skin | SCCIS | antigen processing and presentation of endogenous peptide antigen | 6/919 | 19/18723 | 2.15e-04 | 4.02e-03 | 6 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0414518 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0541618 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0414519 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0541619 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0520312 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-B | SNV | Missense_Mutation | | c.911C>G | p.Ser304Cys | p.S304C | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.806) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-B | SNV | Missense_Mutation | | c.337G>C | p.Glu113Gln | p.E113Q | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
HLA-B | SNV | Missense_Mutation | rs137854727 | c.427N>T | p.Asp143Tyr | p.D143Y | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-B | SNV | Missense_Mutation | | c.1016G>T | p.Gly339Val | p.G339V | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | tolerated_low_confidence(0.15) | probably_damaging(0.952) | TCGA-C5-A7X8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
HLA-B | SNV | Missense_Mutation | rs151341328 | c.595N>A | p.Gly199Arg | p.G199R | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(1) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-B | insertion | Frame_Shift_Ins | novel | c.57_58insTG | p.Thr20Ter | p.T20* | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | | | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD |
HLA-B | insertion | Frame_Shift_Ins | novel | c.244_245insG | p.Glu82GlyfsTer17 | p.E82Gfs*17 | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | | | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HLA-B | insertion | Frame_Shift_Ins | novel | c.696dupC | p.Tyr233LeufsTer21 | p.Y233Lfs*21 | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | | | TCGA-ZX-AA5X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-B | SNV | Missense_Mutation | novel | c.630N>T | p.Lys210Asn | p.K210N | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.615) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-B | SNV | Missense_Mutation | novel | c.148N>T | p.Gly50Cys | p.G50C | P01889,P30480,P30486,Q29836,Q31612,Q31610 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Pazopanib | PAZOPANIB | |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | interferons | | 23360626 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Antithyroid Preparations | | 27157822 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | minocycline | MINOCYCLINE | |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | dapsone | DAPSONE | 28885988,23604100,24152261,29512326,29458119 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | BCG | BCG VACCINE | 17028812 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ticlopidine | TICLOPIDINE | 17339877 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | clozapine | CLOZAPINE | 9587740,26876947,2222133 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | IFN | | 7507709,8081556 |
3106 | HLA-B | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Carbamazepine | CARBAMAZEPINE | |